Cost-Effectiveness Analysis of Dimethyl Fumarate in the Treatment of Relapsing Remitting Multiple Sclerosis: An Italian Societal Perspective

Cost-Effectiveness Analysis of Dimethyl Fumarate in the Treatment of Relapsing Remitting Multiple Sclerosis: An Italian Societal Perspective

BACKGROUND: Delayed-release dimethyl fumarate (also known as gastro-resistant dimethyl fumarate, hereafter dimethyl fumarate) is an oral disease-modifying therapy used for the treatment of Relapsing-Remitting Multiple Sclerosis (RRMS), an autoimmune chronic inflammatory condition of the central nerv...

Full description

Bibliographic Details
Main Authors:	Lorenzo Giovanni Mantovani, Gianluca Furneri, Rossella Bitonti, Paolo Cortesi, Elisa Puma, Laura Santoni, Luca Prosperini
Format:	Article
Language:	English
Published:	SEEd Medical Publishers 2019-07-01
Series:	Farmeconomia: Health Economics and Therapeutic Pathways
Subjects:	dimethyl fumarate, disease-modifying therapy, relapsing-remitting multiple sclerosis, cost-effectiveness, society
Online Access:	https://journals.seedmedicalpublishers.com/index.php/FE/article/view/1437

Similar Items

Delayed-Release Dimethyl Fumarate Safety and Efficacy in Pediatric Patients With Relapsing-Remitting Multiple Sclerosis
by: Raed Alroughani, et al.
Published: (2021-01-01)

Cost–effectiveness of cladribine tablets and dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis in Spain
by: Ricardo Ginestal, et al.
Published: (2023-01-01)

Clinical evaluation of dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis: efficacy, safety, patient experience and adherence
by: Narapureddy B, et al.
Published: (2019-10-01)

Dimethyl Fumarate in the Treatment of Relapsing-Remitting Multiple Sclerosis: Patient Reported Outcomes and Perspectives
by: Ozel O, et al.
Published: (2019-12-01)

Efficacy of Dimethyl Fumarate in Young Adults with Relapsing-Remitting Multiple Sclerosis: Analysis of the DEFINE, CONFIRM, and ENDORSE Studies
by: Lilyana Amezcua, et al.
Published: (2023-04-01)

Increased multiple sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate: a case series
by: Silvia Delgado, et al.
Published: (2021-02-01)

[Tecfidera® (delayed-release dimethylfumarate) in the treatment of relapsing-remitting multiple sclerosis]
by: Lorenzo Giovanni Mantovani, et al.
Published: (2017-12-01)

Patients monitoring during treatment with Dimethyl fumarate (ORP-23)
by: Ali Yousefi Pour
Published: (2023-01-01)

A Real-World Experience of Azathioprine Versus First-Line Disease-Modifying Therapy in Relapsing-Remitting Multiple Sclerosis—A Prospective Cohort Study
by: Arpit Agrawal, et al.
Published: (2023-08-01)

Case Report: Baló's Concentric Sclerosis-Like Lesion in a Patient With Relapsing-Remitting Multiple Sclerosis Treated With Dimethyl Fumarate
by: Karolina Kania, et al.
Published: (2022-05-01)

Dimethyl fumarate as a safe and effective therapy for recalcitrant psoriasis in comorbid patients
by: Martina Burlando, et al.
Published: (2021-10-01)

Effects of dimethyl fumarate on neuroprotection and immunomodulation
by: Albrecht Philipp, et al.
Published: (2012-07-01)

Relapsing–Remitting Multiple Sclerosis Is Characterized by a T Follicular Cell Pro-Inflammatory Shift, Reverted by Dimethyl Fumarate Treatment
by: Vanesa Cunill, et al.
Published: (2018-05-01)

The Antineoplastic Effect of Dimethyl Fumarate on Virus-Negative Merkel Cell Carcinoma Cell Lines: Preliminary Results
by: Thilo Gambichler, et al.
Published: (2023-01-01)

Effectiveness of Dimethyl Fumarate in Real-World Clinical Practice and Strategy to Minimize Adverse Effects and Use of Healthcare Resources
by: Rodríguez-Regal A, et al.
Published: (2021-01-01)

Effect of Rituximab Compared with Natalizumab and Fingolimod in Patients with Relapsing–Remitting Multiple Sclerosis: A Cohort Study
by: Martha Rocio Hernández-Preciado, et al.
Published: (2022-06-01)

Dimethyl fumarate reduces inflammation in chronic active multiple sclerosis lesions
by: Zinger, Nicole, et al.
Published: (2023)

Dimethyl Fumarate Treatment in Patients with Moderate-to-Severe Psoriasis: A 52-week Real-life Study
by: Laura Gnesotto, et al.
Published: (2023-03-01)

A Retrospective Analysis of Real-World Discontinuation Rates with Delayed-Release Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis
by: Michelle Allan, et al.
Published: (2019-12-01)

Dimethyl fumarate for treating Papillon–Lefèvre syndrome
by: Abdullah Al-Omair, MD, et al.
Published: (2023-01-01)

Development and Validation of Fear of Relapse Scale for Relapsing-Remitting Multiple Sclerosis: Understanding Stressors in Patients
by: Ali Khatibi, et al.
Published: (2020-03-01)

Drug-Repurposing Strategy for Dimethyl Fumarate
by: Salvatore Giunta, et al.
Published: (2023-07-01)

Gut microbiota in forty cases of egyptian relapsing remitting multiple sclerosis
by: Sherein G. Elgendy, et al.
Published: (2021-10-01)

Dimethyl Fumarate and Its Esters: A Drug with Broad Clinical Utility?
by: Stephanie Kourakis, et al.
Published: (2020-10-01)

Utilization of dimethyl fumarate and related molecules for treatment of multiple sclerosis, cancer, and other diseases
by: Azzam Maghazachi, et al.
Published: (2016-07-01)

Cognitive profile of patients with relapsing remitting multiple sclerosis
by: VIVIAN M. ANDRADE, et al.
Published: (1999-09-01)

A Bibliometric Evaluation of the Top 100 Cited Dimethyl Fumarate Articles
by: Francisco Javier García-Fernández, et al.
Published: (2021-02-01)

Dimethyl fumarate titration for the systemic treatment of moderate-to-severe plaque psoriasis
by: Giovanna Malara, et al.
Published: (2021-05-01)

Effect and mechanism of dimethyl fumarate on septic cardiomyopathy in mice
by: MIN Weixiang, et al.
Published: (2022-11-01)

Relapsing and Remitting Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits in Association With Infection and Vaccination: A Case Report
by: Simon Moubarak, et al.
Published: (2023-01-01)

Postural Control in Relapsing-Remitting Multiple Sclerosis
by: Flavia Salvaterra Cusin, et al.
Published: (2022-10-01)

The Challenge of Dimethyl Fumarate Repurposing in Eye Pathologies
by: Federico Manai, et al.
Published: (2022-12-01)

Calming the (Cytokine) Storm: Dimethyl Fumarate as a Therapeutic Candidate for COVID-19
by: Cara A. Timpani, et al.
Published: (2020-12-01)

Comparing the Efficacy of Monthly Cyclophosphamide as Monotherapy versus Daily Fingolimod in Relapsing Remitting and Secondary Progressive Multiple Sclerosis
by: Vahid Shaygannezhad, et al.
Published: (2017-08-01)

Vitamin D intoxication in a patient with relapsing-remitting multiple sclerosis – case report
by: Ioana Cociasu, et al.
Published: (2015-09-01)

Repurposing dimethyl fumarate for gastric ulcer and ulcerative colitis: Evidence of local efficacy without systemic side effect
by: Vishal Patel, et al.
Published: (2022-12-01)

The Age-Related Efficacy of Dimethyl Fumarate and Natalizumab in the Real-World Management of Multiple Sclerosis
by: Roberto De Masi, et al.
Published: (2021-01-01)

Dimethyl Fumarate Used as an Effective Treatment for Granuloma Annulare Disseminatum: An Immunohistochemical Case Study
by: Max Gabutti, et al.
Published: (2023-08-01)

Genetic Study of Severe Prolonged Lymphopenia in Multiple Sclerosis Patients Treated With Dimethyl Fumarate
by: Dipen Sangurdekar, et al.
Published: (2019-11-01)

Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients
by: Özlem Taşkapılıoğlu, et al.
Published: (2012-03-01)